Replies to post #148507 on Biotech Values

[Robert C Jonson]

and was intended mainly to deceive unsophisticated investors.


Of course.

It's obvious there can be no other explanation.

Unless, you believe, like Jakedogman1 on the PPHM board that management will do anything to get cheap options.

[kris_kade]

Dew,

I wonder why sell side analysts don't show up in such CC to ask some tough questions. Almost it seems that the so called questions are from some paid pumpers.

[DewDiligence]

Sally Church’s take on Bavituxiamb second-line NSCLC data:

http://pharmastrategyblog.com/2012/09/update-on-bavituximab-in-non-squamous-lung-cancer.html

The above echoes many of the points already made by various posters on this board. Although Sally does not comment on accelerated approval explicitly, it’s clear from the write-up that she agrees with my view in #msg-79408126 that AA is out of the question.